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ABSTRACT
INVOLVEMENT OF PLATELET-DERIVED GROWTH FACTOR, PDGF RECEPTOR
SIGNALING, FOCAL ADHESION KINASE AND SRC IN PRESSURE-INDUCED
VASCULAR SMOOTH MUSCLE HYPERTROPHY
Darian Clark Rice, MID.
Old Dominion University and Eastern Virginia Medical School
August 2002
Director. Russell L. Prewitt, PhD

Elevated blood pressure is associated with varying degrees o f arterial remodeling.
The mechanisms by which extracellular mechanical stress is converted into intracellular
alterations in signal transduction and gene expression have yet to be fully elucidated.
Our goal was to investigate the early events in the vascular smooth muscle response to
acute hypertension and to identify mediators involved in long-term hypertensive
remodeling.
In the acute phase o f hypertension we targeted cell surface integrin and growth
factor receptors thought to be mechanically sensitive. The signaling molecules FAK, Src
and ERK-MAPK are known to be triggered by integrin engagement and growth factor
receptor tyrosine kinase (RTK) activation.

Pairs of rat mesenteric arteries were

pressurized to 90 mmHg (control), and then one was raised to 140 mmHg for I, 3, 5 or 10
minutes. Western blotting using phosphorylation-specific antibodies revealed that SrcpY418 (autophosphorylation site) was elevated 3-fold over control values at 1 minute,
whereas significant FAK-Y397 (autophosphorylation site) activation was observed only
following 3 minutes of pressure stimulus, and was blocked entirely by PP1, a selective
Src inhibitor. Src-pY215 activity, which is associated with prior activation o f the PDGF
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receptor, was not apparent at any o f the time points tested. In addition, peak ERKMAPK activation was identified at 5 minutes and was not affected by the presence o f AG
1296, a PDGF receptor inhibitor. These data demonstrate that autophosphorylation of
Src-Y418 is an early event in pressure mechanotransduction and is required for
downstream FAK-Y397 activation, and PDGF receptor activation does not appear to be
involved in the initial response.
With regard to chronic arterial remodeling, previous studies in our laboratory
showed that PDGF-A mRNA expression is increased in IK. 1C hypertensive rats. We
evaluated the ability o f PDGF-AA to stimulate growth o f carotid vascular smooth muscle
in normotensive rats. Results identified an outward hypertrophic growth response in a
manner similar to that seen in hypertensive remodeling. Next we evaluated the effect o f
PDGF receptor inhibition on vascular hypertrophy and ECM modification in 1K1C
hypertensive rats treated with CGP-53716, a PDGF receptor inhibitor.

Our results

indicated that PDGF receptor inhibition does not block the hypertensive hypertrophic
response, although we found significant changes in extracellular matrix composition.
Overall, it appears that PDGF is not an absolute requirement for hypertrophic remodeling
in 1KIC hypertension, but may play a pivotal role in ECM modification.
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CHAPTER I
INTRODUCTION

Systemic hypertension is known throughout the medical community as the “silent
killer”. Hypertension affects approximately 50 million individuals in the United States
alone. Essential hypertension accounts for 95% o f these cases, and yet the etiology
remains a mystery. Regardless o f etiology, the resulting systemic manifestations have
devastating consequences.

The tremendous morbidity and mortality reflects the

cardiovascular, cerebrovascular, and renovascular complications commonly associated
with hypertension. Therefore, it is o f great importance to gain insight into the molecular
pathophysiological mechanisms which govern this process in order to develop more
specific treatment strategies.
The pathologic changes associated with a chronic elevation in blood pressure
include varying degrees of vascular smooth muscle hypertrophy and structural
remodeling.1' 1 Initially, this may be a “normal” cellular response in order to remain
intact in the face o f elevated pressure, but the long-term consequences of these changes
actually perpetuate the hypertensive state.

The mechanism(s) by which extracellular

mechanical stress is converted into intracellular alterations in signal transduction and
gene expression have yet to be fully elucidated. The increased pressure load produces
increased circumferential wall stress that is somehow translated, or “mechanically
transduced”, into a message that triggers cellular growth and remodeling. The regulation
of such a complex process seems to be multi-factorial in nature, and appears to be

The format o f this dissertation is based on the journal, H ypertension.
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initiated at the cell surface and modulated through interactions between multiple
intracellular signaling pathways.
Cells detect and transmit sensory data from their environment in a variety of
ways. In the case o f hypertension, cell surface receptors or associated molecules may be
the sensors that perceive changes in extracellular pressure, and act as molecular switches
to regulate vascular adaptation. Current evidence suggests that integrins (extracellular
matrix receptors) and/or growth factor receptors may function as cell surface mechanical
sensors. Therefore, we targeted the intracellular signaling molecules Src, Focal Adhesion
Kinase (FAK), and ERK-MAPK (Extracellular Signal-Regulated Kinase o f the MitogenActivated Protein Kinase family), which are associated with integrin receptors, focal
adhesion sites, and growth factor receptor tyrosine kinases (RTK). O f the known RTKs,
preliminary data gathered in our laboratory directed us to specifically explore the role o f
Platelet-derived Growth Factor and its receptor in both acute and chronic arterial
remodeling.
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CHAPTER II
BACKGROUND AND SIGNIFICANCE

Hemodynamics and Hypertension
Flow (Q) is directly proportional to the pressure gradient (AP) and is inversely
related to resistance (R) as represented by the equation Q = AP/R. Blood pressure (AP)
can therefore be defined as the product o f cardiac output (Q) and systemic vascular
resistance (R). Intravascular pressure is very tightly regulated via feedback mechanisms
to ensure proper perfusion o f all bodily tissues. Any alteration in these mechanisms
which leads to an increase in cardiac output or systemic vascular resistance without
compensation may lead to hypertension. In reality, what is seen in the vast majority of
chronic systemic hypertensive subjects is elevated vascular resistance (via reduction of
vessel lumen diameter) at the level o f the small arterioles.

Poiseuille helped us to

understand that the principal determinant o f vascular resistance is vessel radius.

He

expanded the flow equation to account for the contribution o f vessel length (L), radius (r),
and fluid viscosity (r|), Q = jr(AP)rV8qL.

Rearranging this formula to examine the

physical components of hydraulic resistance yields R = AP/Q = 8qL/xr4.3 The fact that
vascular resistance is inversely proportional to the fourth power o f the radius
demonstrates that even small reductions in lumen diameter can cause significant
elevations in blood pressure.
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Vascular Mechanical Forces
As blood pulses through arteries it imparts various mechanical forces on the
vascular wall. Theses forces include fluid shear stress, which is the axial frictional drag
force produced by blood moving across the endothelial surface, and transmural
circumferential wall stress, which is the radial force which causes deformations in the
elastic vessel wall in response to the moving pressure head.

Such forces have a

significant influence on vascular biology and are believed to play a key role in both the
acute regulation of arterial tone and chronic structural remodeling.4
Circumferential wall stress (WS), or “hoop stress”, is the force exerted
perpendicular to the axis o f flow and is related to transmural pressure (P), vessel radius
(r), and wall thickness (WT), by the Law o f LaPlace which states that WS = Pr/WT. Our
focus has been on the vascular smooth muscle cells, which are located beneath the
endothelium and are generally shielded from the direct shear forces o f flowing blood.
Therefore, we hypothesize that transmural wall stress may be the key hemodynamic
factor which directs the cellular response to increases in intravascular pressure.

In

hypertension, arterial vessels thicken their wall via hypertrophy and/or structurally reduce
lumen radius, thereby reducing wall stress, which provides compelling evidence that wall
stress is in fact the governing force behind vascular remodeling. In addition, work in our
laboratory has demonstrated that various cellular growth regulatory mechanisms correlate
with wall stress in pressure-stimulated isolated resistance vessels.5’6
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Vascular Remodeling in Hypertension
Chronic hypertension is associated with increased peripheral resistance to blood
flow.7 As mentioned previously, this phenomenon can be attributed to a structural
reduction in lumen diameter at the level of the small arteries and arterioles. These
"resistance vessels" are vessels with a relaxed diameter o f <400 pm7 and possess an
intrinsic ability to develop myogenic tone.8 This ability to generate spontaneous tone
allows arterioles to vasoconstrict in order to regulate distal flow and counteract an
increase in wall stress due to elevated pressure.9, 10

Over time, the sustained

vasoconstriction will prompt a more permanent structural reduction in lumen diameter
through inward eutrophic remodeling, in which VSMCs within the media reorganize
around a smaller lumen.11 This phenomenon has been demonstrated in both the non
renin-dependent 1-kidney-1-clip and renin-dependent 2-kidney-1-clip experimental
models of chronic hypertension.12,13 Interestingly, once this remodeling has occurred,
vascular tone is returned to normal. Some smaller arterioles will even close completely
(i.e. functional rarefaction), which may then lead to structural rarefaction in which the
vessels atrophy entirely.14 The larger arteries, or "conducting vessels", lack myogenic
tone and eventually undergo outward hypertrophy in order to "tolerate" or counteract the
increase in wall stress. The medium sized arteries located at the transition point between
the conduit and resistance circulation demonstrate intermediate qualities and undergo
both inward and outward hypertrophy (see Figure l).15
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Vascular adaptations associated with the development o f hypertension.
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Anatomy o f the Vascnlar Wall
In order to appreciate the significance o f potential interactions between various
components within the vessel wall, it is important to briefly review vascular anatomy.
The arterial wall can be broken down into three major concentric layers. The innermost
layer is the tunica intima, which consists o f a single layer o f endothelial cells overlying a
thin basement membrane. The subendothelial compartment o f the intima is comprised o f
collagen fibers and vascular smooth muscle cells (VSMCs). The tunica media is the
thickest of the three layers and is composed primarily o f smooth muscle cell layers
housed within a three-dimensional matrix. In chronic hypertension, these VSMCs may
hypertrophy thus increasing wall thickness and/or reorganize thereby reducing lumen
diameter. The outermost layer is the tunica adventitia which largely contains collagen
fibers, fibroblasts, adipocytes and nerve endings.

The Vascular Extracellular Matrix
The vascular extracellular matrix (ECM) is a dynamic system o f fibroelastic
connective tissue organized into a functional lattice.

The principle components o f the

complex three-dimensional network are collagen fibers (types I, HI, IV, V),
proteoglycans, elastin, fibronectin, vitronectin, osteopontin, tenascin-C, laminin, and
proteolytic enzymes (metalloproteinases) involved in the degradation and remodeling o f
the extracellular matrix. Within the vessel wall the smooth muscle cells are the major
source o f ECM protein production.16

Cross-links formed between these various

components provide a mechanically-resistant scaffold, in which cells are anchored and
guided during migration and reorganization. Many o f the components o f the ECM are
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connected to proteins o f the cytoskeleton by transmembrane proteins. At the cell surface,
ECM receptors and cell adhesion molecules create an intercellular communication
network that transmits critical information regarding the current state o f ceil adhesion,
movement, and strain.17' 19 Such interactions provide key sensory information which
regulates cell growth, differentiation, and migration.

Matrix components such as

proteoglycans (i.e. heparin-sulfate, etc.) may even assist with autocrine and paracrine
functions o f growth factors by serving as reservoirs and by regulating receptor
interactions.20

Grako et al found that the transmembrane chondroitin sulfate

proteoglycan, NG2, is required for Platelet-Derived Growth Factor Receptor alpha
(PDGFRa) autophosphorylation and subsequent ellular events in aortic smooth muscle
cells.21

Integrin Receptors
All cells contain membrane-anchored attachment proteins able to recognize
specific motifs in the extracellular matrix and thus form a cellular scaffold. These cellmatrix interactions are primarily mediated by the integrin family o f cell surface ECM
adhesion receptors.

Integrin interaction with ECM components provides a certain

cellular spatial awareness and an ability to sense and react to changes in cell adhesion,
stability, strain, shear stress, as well as respond to a variety o f other cellular stressors. In
vitro experimental models using fibroblasts in a collagen gel have demonstrated that cells
are in mechanical equilibrium with their supporting matrix, and that this interaction is
integrin-dependent, and regulates their growth and determines their biosynthetic
phenotype.22
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Integrins exist in a dynamic state o f flux as heterodimers o f a and P glycoprotein
subunits which associate with ECM proteins such as collagen, fibronectin, laminin,
osteopontin, fibrinogen, thrombospondin and vitronectin. 2 3
formed from combinations o f 17 types of a-subunits and

8

Twenty-two heterodimers

types o f P-sub units have been

identified thus far and differ with regard to substrate specificity. The predominance of
aiPi, CZ3 P1 , asPi, avpi and avP3 integrins in vascular smooth muscle cells (VSMC) suggests
significant dependence on fibronectin, collagen, and laminin. 2 4 In hypertension, Bezie et
al have found increased total fibronectin and asPi integrin in arterial vessels of
spontaneously hypertensive (SHR) rats. 2 5 In addition, VSMCs exposed to mechanical
strain demonstrated a 48% increase in fibronectin and a 50% increase in collagen. 2 6
Mercurious et al found that when the fibronectin-integrin interface was disrupted with the
recombinant fibronectin fragment, protein HI l-C, VSMC proliferation was reduced by
75-90%.27 Overall, these data provide substantial evidence that integrin interaction with
ECM constituents plays a key role in the regulation o f cellular growth. Therefore, we
hypothesize that these growth responses may be exaggerated in VSMCs exposed to a
pressure stimulus.
Integrin engagement by ECM constituents completes a bridge linking the
extracellular matrix to an intracytoplasmic domain containing both cytoskeletal and
catalytic signaling components. Upon recognition of the extracellular ligand, activated
integrins cluster to form focal adhesion sites and initiate the polymerization o f actin stress
fibers. Engagement o f the Pi integrin subunit by fibronectin recruits actin, vinculin, talin,
and a-actinin which direct the assembly o f actin stress fibers via a rho-dependent
mechanism to help the cell adapt to changes in shape, adhesion and mechanical stress.-
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Interestingly, Davies et al found that focal adhesions formed in endothelial cells exposed
to shear stress in the form o f unidirectional laminar flow actually realign themselves
along the axis o f flow, thereby reducing cellular tension.29
In addition to the formation o f actin stress fibers, integrins transmit critical growth
regulatory signals.

Integrins do not intrinsically possess kinase activity, but upon

activation recruit the assembly o f several adaptor molecules and cytosolic protein
kinases. Integrin engagement thereby initiates an intracellular phosphorylation cascade
which transmits critical information regarding the state o f adhesion, migration and strain.
The cell utilizes such data to direct growth, migration, proliferation, spreading, and to
ultimately determine cell survival (see Figure 2).17’18' 3(K33

Focal Adhesion Kinase
Focal adhesion kinase (FAK) appears to be a central player in integrin signaling.
FAK has been shown to associate not only with integrins and focal adhesion complexes,
but also cell-to-cell cadherins/pecams, and growth factor receptor tyrosine kinases. FAK
is a cytosolic protein tyrosine kinase (PTK), which upon activation, i.e. phosphorylation,
has been shown to provide a substrate for association and activation o f other cytosolic
proteins such as Src, phosphatidylinositol 3-kinase (PI3K), Grb2, paxillin, and pHO^15.
Six FAK tyrosine phosphorylation sites have been identified (Y397, Y407, Y576, Y577, Y861,
and Y925), which allow for the specific recruitment o f these proteins. Tyrosine residue
397 (Y397) is the major site o f FAK autophosphorylation and serves as a docking site for
the SH2/SH3 (Src homology 2/3) domain o f Src34 and PI3K. PhosphatidyIinositoI-3
kinase (PI3K) recruited by pY397 serves as an important regulator o f protein kinase B
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Figure 2. Diagrammatic representation o f the involvement o f integrins in cellular growth
and survival, (courtesy o f Calbiochem)
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(PKB, or Akt) and C (PKC), which act to inhibit apoptosis and promote cellular
growth.35*36 pY407 and pY861 appear to promote further SH2 domain binding, although
their roles remain unclear. pY925 has been shown to attract Grb2, an adaptor protein
which initiates the Erk 1/2 MAPK cascade.37"43

The Src Family of Protein Tyrosine Kinases
Src is another family of cytosolic non-receptor protein tyrosine kinases (PTK)
which are involved in various signal transduction pathways associated with vital
processes such as cell growth, adhesion, and differentiation. Src is a 60 kD protein
comprised o f six distinct functional domains: SHI (Src Homology I) is the catalytic
kinase domain; SH2, SH3, and a unique domain regulate interactions with target
substrates, SH4 ts a reversible membrane binding region, and the C-terminal region
which plays a significant role in the regulation o f Src kinase activity.

Like other

tyrosine kinases, Src catalyzes the transfer o f phosphate from ATP to tyrosine residues on
target proteins. Src kinase activity is tightly regulated via two major phosphorylation
sites. Phosphorylation o f Src tyrosine 416 (Y416) within the catalytic site of the SHI
domain enables full activation o f the kinase. Src-Y527 is located in the C-terminal region
and is the site o f negative regulation, which when phosphorylated, renders the Src
molecule inactive. C-terminal Src kinase (Csk) acts to maintain Y-527 phosphorylation
in the absence o f substrate binding. Intramolecular interactions between the SH2 domain
and the C-terminal phosphotyrosine 527 fold and stabilize the Src molecule in a closed
inactive conformation. However, binding o f protein targets in the SH2 or SH3 region, or
loss o f Y527 phosphorylation, disrupts the closed conformation and makes tyrosine 416
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accessible for phosphorylation.44 Aside from substrate binding, Src-Y416 may also be
activated via autophosphorylation induced by such triggers as mechanical stress45 despite
inhibition by Src-pY527. Src-pY416 may then further act by dephosphorylating Src-Y527 to
allow full activation o f the Src molecule (see Figure 3).34’ 37' 44, 46*51 An additional
phosphorylation site, Src-Y215, has been identified which correlates with Src activation
following recruitment by an activated PDGF receptor.52
Src is intimately involved in the propagation o f various intracellular signaling
cascades. Once recruited and/or activated, Src continues the phosphoregulatory cascade
by association with various target proteins, kinases, and adapter molecules displaying
SH2/SH3 domains. Known protein targets o f Src include the pi integrin; the integrindependent signaling molecules FAK, rho, paxillin, talin, vinculin, and tensin; PI-3 kinase;
PLCy; and She and Ras, which are associated the Mitogen-Activated Protein Kinase
(MAPK) growth regulatory signaling cascade.44 In hypertension, work in our laboratory
has recently shown that Src is required for ERK-MAPK activation and c-fos induction in
pressure-stimulated resistance arteries.53

The Mitogen-Activated Protein Kinases
The Mitogen-Activated Protein Kinases (MAPK) are a highly conserved family of
serine/threonine kinases that are key regulators o f cellular growth. MAPKs appear to be
activated by integrin engagement, cell stressors (mechanical strain, heat shock, osmotic,
oxidative), and growth factor receptor activation (ex. PDGF-R, EGF-R, ATI). Three
major subfamilies o f MAPKs have been identified and include ERKs (Extracellular
Signal-regulated Kinases), JNKs/SAPKs (c-Jun N-terminal Kinases or Stress-activated
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Figure 3. A. A computer-generated image o f the three-dimensional structure of Src. B.
An illustration o f the regulation o f Src kinase activity controlled primarily by Y416 and
Y327 phosphorylation, (reproduced with permission from Schlessinger. J.. J Biol Chem
1998)47
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Protein Kinases), and p38 MAPKs. These MAPKs are believed to play a critical role in
the regulation o f cellular events such as cell growth, differentiation, and apoptosis. 5 4 ’ 5 5
ERK is activated primarily by growth factor receptor tyrosine kinase (RTK)
stimulation, integrin engagement, or by angiotensin II (AH) binding to the AT-1 receptor.
Autophosphorylation o f specific tyrosine residues in the activated RTK or stimulation of
the G-protein coupled AT-l (Gq) receptor have been shown to recruit Grb2, an adaptor
molecule, which appears to be the switch that activates the MAPK pathway.
Subsequently, Grb2 forms a complex with Sos, a nucleotide exchange factor, and then
converts Ras to its active GTP-bound form.

The newly phosphorylated Ras then

activates Raf-l, a serine/threonine kinase, which stimulates MAPK kinase (MEK) to
phosphorylate ERK. Activated Erk 1/2 subsequently translocates to the nucleus where it
stimulates ternary complex factors (TCF) such as Elk-1 to bind serum response factor
(SRF). The TCF-SRF complex then binds the serum response element (SRE) located
within the promoter o f proto-oncogenes such as c-fos, c-jun, and c-myc. The newly
synthesized Fos and Jun proteins then dimerize to form the AP-I transcription factor
which modulates the expression o f target genes during various stages o f the cell cycle
(see Figures 4 and 5) . 5 5 - 6 1 To prevent overexpression, feedback regulatory mechanisms
such as MAPK phosphatase-1 (MKP-1) have been identified which are upregulated and
inactivate MAPKs after stimulation by mitogens or cellular stress. 6 2
Erk 1/2 has also been implicated in the activation o f p90 S6 kinase.63’ 6 4 The
ribosomal protein S6 is thought to be one o f the key regulators o f protein synthesis.
Phosphorylation o f S6 by p70 S6 kinase or p90 S6 kinase is correlated with an activation
o f protein synthesis at the level o f initiation. The upstream components responsible for
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Figure 4. Diagrammatic representation o f the Erk-MAPKinase pathway in response
to mitogen stimulation. (Courtesy of Sigma-Aldrich)

Figure 5. Transcriptional regulation by activated Erk-MAPK. (Courtesy o f SigmaAldrich)
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p70 S6 kinase activation include growth factor or ATI receptor induced Erk 1/2 and PI3K.

Implications for Collaborative Signaling in Hypertensive Hypertrophic Remodeling
With regard to hypertension, Li et. al. have recently demonstrated that cyclic
stretch o f aortic smooth muscle cells induces ERK 1/2, JNK, and p38, as well as MAPK
phosphatase-1. 6 2 * 6 5 MacKenna et al have suggested that mechanical stress may stimulate
ERK through the action o f c-Src, which is associated with focal adhesion kinase (FAK) at
focal adhesion sites. 6 6 Sieg et al and others found growth factor receptors such as EGFR, PDGF-R and AH-ATI receptors colocalized within focal adhesion sites67"69.
Miyamoto et al further demonstrated that integrin occupancy by ECM ligands triggers not
only integrin clustering but also induces the aggregation o f PDGF (platelet-derived
growth factor), EGF (epidermal growth factor), and bFGF (basic fibroblast growth factor)
receptors at the sites o f integrin clustering. ' 0 Interestingly, both PDGF and EGF induce
focal adhesion formation via activation of members o f the ras family o f GTP-binding
proteins. 71 Interactions between integrins and ECM components have also been shown to
regulate growth factor availability and receptor binding. Jones et al have demonstrated
that interactions between a vp3 integrins and tenascin-C to promote epidermal growth
factor (EGF)-dependent growth in VSMCs. 7 2 In addition, Grako et al have shown that
PDGFRa autophosphorylation is inhibited in aortic VSMCs lacking the ECM
transmembrane proteoglycan, chondroitin sulfate NG2. 2 1

These findings suggest the

possibility that integrins and growth factor receptors may collaborate in pressure-induced
VSMC hypertrophy.
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But which o f these growth factors is responsible for pressure-stimulated growth in
intact vessels? In an attempt to identify the mediators o f pressure-induced hypertrophy,
Parker et al in our laboratory investigated the role o f AH via the ATI receptor. In lkidney-l-clip (1K1C) hypertensive rats, she demonstrated that ATI inhibition with
losartan fails to inhibit the VSMC hypertrophy. 7 3 Berk et al reported that All-mediated
hypertrophy o f vascular smooth muscle cells requires the presence o f PDGF-AA. 7 4
Interestingly, Dobrian et al showed that PDGF-A, but not PDGF-B, mRNA expression is
upregulated in IK 1C non-renin dependent hypertensive rats, and that the expression
directly correlated with blood pressure. ' 5

In spontaneously hypertensive rats (SHR),

Kitami et al have shown that increased PDGF-AA production directly contributes to the
hypertrophy o f vascular smooth muscle cells (VSMC), and also found increased mRNA
expression o f the PDGF alpha receptor (PDGFRa) . 7 6 Data gathered by Mulvany et al
(data not published) has shown that ERK 1/2 is maximally activated at 5 minutes by
PDGF, All, and pressure, an effect that is completely abolished by the PDGF receptor
inhibitor, RPR 101115A.

Interestingly, Hu et al demonstrated that the PDGFRa in

VSMCs is activated by mechanical stress even in the absence o f ligand. 7 7 These data
provide compelling evidence that the PDGF receptor may be the key element in pressureinduced hypertrophic signaling. Therefore, the role o f PDGF and its receptor has become
the target o f our current investigation.

Platelet-Derived Growth Factor and Its Receptor
Platelet-Derived Growth Factor (PDGF) is a polypeptide that was originally
described by Ross et al. in 1974 as a platelet-dependent serum factor that potently
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stimulates cell proliferation and migration in vascular smooth muscle cells78. Since then,
others have extended the spectrum o f PDGF expression to include all cells o f
mesodermal origin including endothelial cells, smooth muscle cells, fibroblasts, and
placenta. 7 9
In vivo, PDGF exists as a disulfide-linked dimer o f A and B polypeptide chains
which combine to form the three isomers PDGF-AA (26.5 kDa), PDGF-AB (25.5 kDa),
and PDGF-BB (25.0 kDa). The A chain (PDGF-A) occurs in two versions as a result o f
alternative splicing. The longer isoform (PDGF-AL) possesses a highly basic carboxyterminal extension that is responsible for retaining PDGF-AL homodimers at the cell
surface after secretion, while homodimers o f the shorter isoform (PDGF-AS) are freely
released into the extracellular space. Thus, PDGF dimers that contain PDGF-AL may
assist in autocrine action by virtue of binding to heparin-like constituents o f the ECM. In
fact, Fukuda et al have shown that the long-form o f PDGF A-chain contributes to the
exaggerated growth o f VSMC from SHR . 8 0
Once formed, the PDGF-AA, -AB, and -BB dimers differ in their cellular
growth-promoting effects depending upon the receptor and cell type stimulated. The
PDGF receptors belong to a family of cell surface growth factor receptor tyrosine kinases
(RTKs) which are formed by the dimerization o f a and/or P receptor subunits to yield
a a , a p , and PP receptor subtypes.

In vascular smooth muscle cells, PDGF appears to

regulate protein synthesis and cell growth via these receptors in an autocrine and
paracrine manner. 8 1

In addition, Sjolund found that inhibition of extracellular PDGF

binding by suramin did not prevent autocrine stimulation o f DNA synthesis.

This

suggests that newly synthesized PDGF may have the ability to activate its receptor
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intracellularly and that autocrine action does not require release into the pericellular
space. 82
The PDGF receptors demonstrate differential binding affinity for the three PDGF
isoforms. The aa-receptor has been shown to bind all three isoforms, whereas the aPreceptor will preferentially bind PDGF-AB and PDGF-BB, and the PP-receptor displays
an affinity only for PDGF-BB. Activation o f these PDGF receptors by ligand binding or
another mechanism initiates a cascade o f growth regulatory signals. The key event in the
activation o f the PDGF receptor is the dimerization o f the two cytoplasmic tails that
juxtapose various tyrosine residues and allow for trans-phosphorylation o f the internal
receptor components. The function o f autophosphorylation is to regulate the catalytic
activity of the receptor kinase and provide docking sites for downstream signal
transduction molecules.

The tyrosine autophosphorylation sites recognize binding

domains such as Src homology 2 and 3 (SH2/SH3), phosphotyrosine binding (PTB)
domains, and pleckstin homology (PH) domains.

Several SH2-containing signaling

molecules have been identified and include the Src family o f tyrosine kinases, FAX,
phosphadidylinositol 3-kinase (PI-3K), phospholipase C-y (PLC-y), the tyrosine
phosphatase SHP-2, and the GTPase activating protein for Ras (GAP).

Adapter

molecules such as Grb283, She, Nek, Grb7, and Crk are also recruited.

Further

downstream, these molecules propagate the signal by phosphorylating other targets such
as protein kinase C (PKC), phospholipase D (PLD), Akt, S6 kinase, and the signal
tranducers and activators of transcription (STATS) to promote cellular growth,
proliferation and survival. 8 4 * 8 5
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In vascular smooth muscle cells (VSMC), Inui et al and others found that
signaling mechanisms via PDGF-a and *P receptors distinctly differ in downstream signal
transduction events.

PDGF-BB is the most potent mitogen and stimulates DNA

synthesis, actin filament rearrangement, anti-apoptotic mechanisms, and regulates
calcium availability. 8 6 - 8 8

Stimulation by PDGF-AA primarily induces cellular

hypertrophy (protein synthesis), but not hyperplasia, and also has a greatly diminished
ability to regulate intracellular calcium . 8 4 , 8 6 , 8 7 , 8 9 - 9 2 These effects were further determined
to result from differential activation o f critical signaling molecules. The mitogenic action
o f PDGF-BB seems to be under the control o f PLD-dependent formation of phosphatidic
acid (PA), whereas PDGF-AA does not cause an increase in PA production. Thus, PA
may be a significant second messenger in the activation o f DNA synthesis by PDGFBB. 8 7 In addition, Salhany et al have shown that PDGF-stimulated modulation o f gene
expression occurs at least in part by induction o f the immediate-early c-fos gene and by
activation o f the serum response element (SRE) . 9 3 Interestingly, Allen et al have detected
significant c-fos expression in pressure-stimulated isolated vessels5, which is consistent
with PDGF receptor-mediated signaling events.

Hypertension and ECM Modification
Extracellular matrix (ECM) modifications in the vascular wall may also
contribute to arterial remodeling in hypertension. The current thought is that
Transforming Growth Factor Beta (TGF-|3) and PDGF primarily govern the production
o f ECM components. Halloran et al found that TGF-beta I regulates type I procollagen
expression in adult human arterial SMC in part by inducing PDGF-A as a co-factor. 9 4
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Pressure or mechanical stress has also been shown to stimulate the synthesis of
extracellular matrix (ECM) components such as collagen I & m , hyaluronate, and
chondroitin-6 -sulfate . 9 5

Satoh et al have suggested that enhanced expression o f TGF-

betal, PDGF A-chain, AH, and bFGF may contribute to the exaggerated growth and
remodeling o f VSMC from SHR. 9 6 Bezie et al found increased cell-matrix attachment
sites and total fibronectin in SHRs as compared to normotensive Wistar rats which
suggests a role for both cellular and matrix components in vascular mechanical
adaptation. 2 5

Therefore, in addition to promoting growth in vascular smooth muscle

cells, PDGF may also coordinate ECM component production 9 7 and contribute to arterial
remodeling in response to hypertension.
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CH APTER m
HYPOTHESES

I.

The first hypothesis is that the PDGF receptor is activated by a pressure
stimulus, even in the absence o f ligand.

II.

The second hypothesis is that Focal Adhesion Kinase, which is associated with
integrin receptors and focal adhesion complexes, may initiate the hypertrophic
response by autophosphorylation at Y-397.

HI.

The third hypothesis is that the Src family o f cytosolic tyrosine kinases facilitates
the activation o f Focal Adhesion Kinase and/or the PDGF receptor.

IV.

The fourth hypothesis is that Platelet-derived Growth Factor AA directly
stimulates hypertrophy in vascular smooth muscle cells and regulates extracellular
matrix production.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

24

CHAPTER IV
SPECIFIC AIMS

The overall objective o f this research was to identify the mechanism(s) by which
increased pressure stimulates hypertrophy in the vessel wall, specifically, the
involvement o f platelet-derived growth factor, its receptor signaling, and the early events
in the vascular response to hypertension. The specific aims were to:

1.

Identify the molecular pressure sensor(s) that initiates or facilitates the
phosphoregulatory cascade leading to VSMC hypertrophy. Candidates that were
investigated include the Src family o f cytosolic protein kinases, Focal Adhesion
Kinase (FAK), the Extracellular Signal-regulated Kinase subtype o f the Mitogen
Activated Protein Kinase (ERK-MAPK) family o f intracellular messengers, and
PDGF receptor activation in response to pressure stimulus in isolated resistance
arteries.

2.

Determine the role o f Platelet Derived Growth Factor AA isoform (PDGF-AA) in
the initiation o f vascular smooth muscle hypertrophy, by direct infusion onto the
carotid artery in normotensive rats.

3.

Determine the influence o f Platelet Derived Growth Factor Receptor blockade in
the hypertrophic response to hypertension, by utilizing the PDGF-R antagonist,
CGP-53716, in 1K1C rat model o f chronic hypertension in rats. For acute studies.
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isolated vessels were pretreated with AG1296, a specific inhibitor of the PDGF
receptor, pressurized and then analyzed for downstream ERK 1/2 activation.
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CH APTER V
M ATERIALS AND METHODS

All experimental procedures were approved by the institutional Animal Care and
Use Committee.

Isolated Dual Vessel Protocol
Male wistar rats (200-410 g) were anaesthetized with pentobarbital (60 mg/kg IP).
After midline laparotomy and perforation o f the heart, the mesenteric arcade was
carefully dissected away from the associated length o f intestine, and placed in cold (4° C)
bicarbonate-free physiological saline solution (PSS), with the following composition (in
mmol/L): NaCl 141.8, KC1 4.69, MgSCL 1.59, EDTA 0.513, CaCl2 2.79, HEPES 10.0,
KH2 PO4 1.18, and glucose 5.0, adjusted to a pH o f 7.37-7.4. First order mesenteric small
arteries were then cleared free o f surrounding adipose tissue and mounted in a dual vessel
chamber (Living Systems Instrumentation, Burlington, VT, USA, model CH/2/M).
Isolated arteries were cannulated onto tapered glass micro-pipettes (outside diameter 210
- 250 pm) with the aid of a dissection microscope, and were secured using 19 pm nylon
filament. Once the vessels were mounted, the chamber was transferred to the stage o f an
upright microscope (Zeiss), where the transilluminated vessels could be visualized on
CCTV. The internal and external diameters were measured and recorded with the aid o f
video calipers (Texas A&M). The intraluminal pressure was controlled by adjusting the
height o f a fluid reservoir, and was recorded continuously via pressure transducers. The
pressure in both vessels was gradually raised in a step-wise fashion (15 mmHg every 15
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minutes) to a normal mean arterial pressure o f 90 mmHg, at 37° C. Following a 1-hour
equilibration at 90 mmHg, one o f the vessels was raised to a hypertensive pressure of 140
mmHg for 1, 3, or 5 minutes, while the other remained at 90 mmHg to serve as the
experimental control.
In order to reduce variability, all experiments were performed in a paired fashion,
and both arteries were isolated from the same rat. For experiments evaluating the role of
Src in pressure mechanotransduction, PP1 (10 pM). a specific inhibitor o f Src that does
not interfere with FAK autophosphorylation 98, was administered extraluminally in the
tissue bath during the I-hour equilibration period. AG 1296, a specific inhibitor o f the
PDGF receptor, was administered in the same fashion.

Tissue Homogenation Protocol
At the endpoint o f each experiment, both vessels were removed from the cannula,
immediately snap frozen in liquid nitrogen, and then ground in 50 pL of cold
radioimmunoprecipitation (RIP A) protein extraction buffer o f the following composition:
Tris 50 mmol/L, NaCI 150 mmoI/L, 1% NP-40, 0.25% Na-deoxycholate, and EDTA I
mmol/L.

In addition, the buffer also contained the protease inhibitors, Aprotinin I

pg/mL, Leupeptin I pg/mL, Pepstatin Ipg/mL, and Phenylmethylsulphonylflouride
(PMSF) I mmol/L, and the phosphatase inhibitors, sodium orthovanadate (NajVCXi) 1
mmol/L and sodium fluoride (NaF) 1 mmol/L.

The tissue homogenate was then

centrifuged at 11,000 rpm for 20 minutes and the supernatant transferred to an eppendorf
tube. Samples were then stored at -70°C until further processing.
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Micro Bicinchoninic Acid (BCA) Protein Assay
The total protein content o f each vessel homogenate was determined using the
Micro-BCA (bicinchoninic acid) protein assay (Pierce). For small protein samples, the
Micro-BCA assay is a sensitive method for quantitative colorimetric determination of
total protein content in dilute aqueous solutions (0.5-20 pg/ml).99

The Micro BCA Protein Reaction Scheme:
1.

Protein (peptide bonds) + Cu2+-t- OH* -> tetradentate-Cu1* complex

2.

Cul+ complex + BCA -> BCA-Cul+ complex (purple colored)

3.

Read absorbance at 562 nm

A standard curve was first generated by preparing serial dilutions o f a BSA stock
standard (2 mg/ml). The protocol required I ml o f each standard dilution or 5 pi of
protein sample + 995 pi dHiO to be placed in a clear cuvette. One ml of working reagent
(25 parts Micro BCA reagent A, 24 parts reagent B, and I part reagent C) was added to
each standard and sample. The tubes were then incubated for 60 minutes at 60°C. Once
cooled to room temperature, the absorbance was measured at 562 nm vs. a water
reference. Using the standard curve, the protein concentration o f each unknown sample
was determined.

Sodium Dodecyl Sulfate - Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were standardized and prepared with dithiothreitol (DTT) and
Laemmli buffer (10% SDS, 0.3125 M Tris, 50% glycerol, 25% P-mercaptoethanol, 0.5%
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bromophenol blue).

Equal amounts o f protein were then loaded and separated by

electrophoresis (45 minutes at 180-200 V) using a 7.5-12% SDS-polyacrylamide gel. A
prestained rainbow markers (Amersham Pharmacia Biotech) was used as a molecular
weight standard.

Western Blotting
Following SDS-PAGE, the gel was equilibrated in transfer buffer (25 mM Tris,
192 mM glycine, 20% MeOH) prior to transferring the protein to PVDF membranes (100
V x 60 min or 110 V x 75 min). The membrane was blocked in a 1:1 solution o f non
animal protein NAP-Sure Blocker (Geno Technology) and Tris-buffered saline with 1%
Tween-20 (T-TBS) for I hour at room temperature (RT). Membranes were incubated
with a polyclonal phosphorylation-specific 1° antibody for 1-2 hours at RT, followed by
alkaline phosphatase conjugated goat anti-rabbit secondary antibody (Tropix) for I hour.
Membranes were then washed in T-TBS followed by Assay buffer (20 mM Tris, 1 mM
MgCh, 0.1 M diethanolamine, pH 9.8-10.0) prior to incubation with the developing
reagent (CDP-Star, Tropix). The enhanced chemiluminescent (ECL) signal was detected
by Kodak Digital Imaging System, and the band signal intensity was quantified using
SigmaGel digital software.

Western Reprobe Protocol
The membrane was first washed in T-TBS for 5 min, placed in a 50 ml Falcon
tube, and then “stripped” o f bound antibodies using Reprobe solution (16 ml dHiO +- 4
ml 5x Reprobe solution) for 20 minutes. After stripping, the membrane was washed in T-
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TBS 3 x 5 minutes and then in Assay buffer 2 x 2 minutes. The blot was then drained
and covered with 3 ml Tropix Developing Reagent (CDP-Star) for 5 minutes at room
temperature.

The membrane was then allowed to develop for 30 minutes and then

imaged using Kodak Digital Imaging software (to confirm successful stripping). The
membrane was then ready for incubation with 1° antibody.

1-Kidney, 1-Clip (1K1C) Surgical Procedure
Anesthetized (ketamine-HCl 80 mg/kg and xylazine 12 mg/kg, or pentobarbital
60 mg/kg IP) male Wistar rats (200-350 g) were placed in anatomic position on a sterile
drape. Following the induction o f surgical anesthesia, a midline abdominal incision was
made and the left renal vascular bundle exposed by blunt dissection. The renal artery and
vein were carefully separated to isolate the renal artery and to allow careful placement of
the silver Goldblatt clip (230 pm gap). The kidney was then monitored for adequate
renal perfusion. Once the left renal artery was stabilized, the right renal artery was
exposed for the placement o f two ties around the artery-vein bundle. The right kidney
was then removed by clipping between ties and then bluntly dissecting the surrounding
connective tissue kidney capsule.

The muscular abdominal wall was closed using

interrupted or running 4-0 Vicryl sutures. The skin incision was then closed by skin
stapling or placement of several interrupted stitches using 5-0 nylon sutures.
precautionary measure, penicillin G 25,000 U EM was also given.
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Surgical Placement of Carotid Catheter and Mini-osmopump

Anesthetized (pentobarbital 60 mg/kg IP) male Wistar rats were placed on a
sterile drape-covered cork board in anatomic position. Hypothermia was prevented by
placing the surgical board on a heating pad. Surgery was performed with the aid o f a
dissection microscope, using sterile technique. A midline incision (1-1.5 cm) was first
placed in the anterior neck. The right common carotid artery was exposed by careful
blunt dissection between the trachea and sternocleidomastoid muscle. Micro-retractors
were used to aid in the exposure. Once the right carotid artery was carefully freed o f
surrounding vessels and nervous tissue, a specially designed catheter (microrenathane
tubing perforated at the site o f anticipated saline or PDGF-AA delivery) was placed
parallel and adjacent to the carotid. The catheter was then secured by placing a cuff
around both the catheter and carotid, and by directly suturing to nearby musculature.100
Once secure, the distal end o f the catheter was tunneled subcutaneously around the base
o f the lateral right neck and between the scapulae where the catheter was attached to a
mini-osmopump (Alzet Model 2002, Alza Corp, Palo Alto, CA) with a pumping rate of
0.5 p.1/hr x 14 days. The connection between the catheter and minipump was reinforced
with a suture to prevent disconnection during the course o f the experiment. All incisions
were closed with surgical staples or interrupted stitches.

Paraffin Tissue Embedding and Slide Preparation Protocol
Tissues harvested for staining or immunohistochemistry were first placed in
labeled tissue paper, and allowed to bathe in 10% phosphate-buffered formalin for a
period o f 4 hours. The tissues were then processed through graded ethanol solutions in
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an automated tissue processor (Technicon) overnight.

Once processed, tissues were

vertically oriented in plastic tissue trays and embedded in hot paraffin wax. Once cooled,
tissues were ready for microtome sectioning and slide preparation.

Immunohistochemistry for PDGF-AA
Slides o f paraffin embedded tissue were placed in a slide carrier and warmed in an
oven at 55°C for I hour. Slides were then deparaffinized and rehydrated by washing in
xylene ( 3 x 5 minutes), then 100% EtOH (3 x 10 minutes), followed by 95% EtOH (2 x
10 minutes), and finally in 70% EtOH (I x 10 minutes). The slides were then rinsed in
distilled H2 O for 5 minutes. Next, the slides were incubated with 0.3% H2 O2 in cold
methanol (200 ml MeOH + 6 ml H2 O 2 ) for 30 minutes in order to block the endogenous
peroxidase and permeabilize the tissue. The slides were then washed in PBS (for 2 x 5
minutes) prior to preincubation with 5% normal goat IgG (NGS) in PBS/0.1%BSA (30
minutes) to block nonspecific binding. The next step involved incubation with the 1°
antibody (dilution 1:100 in PBS/NGS/0.i%BSA) in a humidification chamber for 2 hours
at room temperature (or 4°C overnight). The slides were then washed in PBS ( 3 x 5
minutes) and PBS/0.1%BSA (15 minutes) prior to incubation with the biotinylated 2°
antibody (goat anti-rabbit IgG) (dilution 1:500 in PBS/0.1%BSA) for 30 minutes. Next,
the slides were washed in PBS ( 3 x 5 minutes) and PBS/0.1% BSA (15 minutes), prior to
incubation with Vectastain for 30 minutes.

Slides were then washed in PBS for 10

minutes and then rinsed in 1% TritonX-100/PBS for 30 seconds. Once allowed to air
dry, the slides were incubated with 0.1% diaminobenzene (DAB) Metal/Stable Peroxide
Buffer for 5-15 minutes slides in a humidification chamber, until brown staining was
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visible. The slides were then washed under cold running tap water for 5 minutes, and
then counterstained with hematoxylin for 3 minutes. The slides were once again washed
under cold tap water for 5 minutes. Dehydration and clearing involved washing the
slides in 70% EtOH (2 x 10 minutes), followed by 95% EtOH (2 x 10 minutes), then
100% EtOH (2 x 10 minutes), and finally xylene (2 x 10 minutes). After the final step,
slides were allowed to air dry prior to applying a coverslip. The slides were then ready
for microscopic evaluation.

Immunocytochemistry for BrdU

Incorporation o f bromo-deoxyuridine (BrdU) in the nuclei was used as a marker
o f DNA replication during the infusion period. Sections o f paraffin-embedded tissues
were deparaffinized, rehydrated, and blocked for endogenous peroxidases. DNA was
denatured by treatment with 2N HC1 for 30 minutes at 37°C, enzymatically pretreated
with trypsin, and then incubated with 5% normal goat serum (NGS). Tissues were then
incubated with mouse monoclonal anti-BrdU, while negative control sections were
incubated in 5% NGS.

All tissues were then incubated with biotinylated secondary

antibody IgG, stained with Vectastain Elite avidin-biotin complex kit, and incubated with
0.1% diaminobenzene (DAB) in Stable Peroxide Buffer. Kidneys from each animal were
also evaluated for the incorporation o f BrdU as a positive control.

Totuidine Blue Staining
Thin sections (5 pm) o f paraffin-embedded tissue were stained with toluidine blue
to assist in the visualization o f the vascular intima and media.
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deparaffinized in xylene (3 minutes x 2), then rehydrated in 100% EtOH (10 dips x 3),
95% EtOH (10 dips x 1), and then dHzO (5 minutes). Slides were then placed on a
warmer at 37°C and stained with toluidine blue dye for I minute. Excess dye was rinsed
off with dHjO prior to dehydration using 95% EtOH (10 dips), 100% EtOH (10 dips),
and xylene (3 minutes x 2).

Pico-Sirius Red Staining
Thin sections (5 pm) o f paraffin-embedded tissue were stained with Pico-Sirius
Red to allow the quantification o f total collagen in the vascular wall using NIH digital
imaging software.

Slides were first deparaffinized in xylene (5 minutes x 3), then

rehydrated in 100% EtOH (1 min x 2), 95% EtOH (I min), 70% EtOH (I min) and then
dHzO (I min). Slides were then stained with Pico-Sirius Red dye for I hour, followed by
2 washes in 30% acetic acid and dehydration using 70% EtOH (20 dips), 95% EtOH (20
dips), 100% EtOH (20 dips), and xylene (20 dips x 3).

Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Total RNA was isolated by first homogenizing tissues in guanidine isothiocyanate
(GITC) and (3-mercaptoethano 1 (BME). The RNA was further separated from DNA and
proteins by cold ethanol precipitation followed by total RNA recovery using a GlassMax
RNA Micro-isolation Spin Cartridge System (GIBCO).

The total RNA was reverse

transcribed by incubating the sample at 42°C for 30 minutes in the presence of
Oligo(dT)i5 primer, AMV reverse transcriptase, dNTPs, MgCh and ribonuclease
inhibitor (Promega Reverse Transcription System, Cat. # A3500). The reaction mixture
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was heated to 95°C for 5 minutes and then rapidly cooled to 4°C to inactivate the reverse
transcriptase and prevent it from binding to the newly formed cDNA. The cDNA was
then amplified using Fa^BEAD Hot Start Polymerase (Promega, Cat.# M5661), dNTPs,
MgCl2 and primer pairs for either Collagen I, Collagen LH, or PDGF-A. Cyclophilin was
used as the reference housekeeping gene. The following rat sequences were used as
primers: I) COL 1: 5’-TGCCGTGACCTCAAGATGTG-3\ 5’-CACAAGCGTGCTGTAGGTGA-3

2) COL LH: 5’-AGATCATGTCTTCACTCAAGTC-3\ 5’-TTTAC-

ATTGCCATTGGCCTGA-3’; 3) PDGF-A: 5’-AAGCATGTGCCGGAGAAGCG-35’TCCTCTAACCTCACCTGGAC-3’; and 4) Cyclophilin: 5’-GTCGCGTCTGCTTCGAGCTGTTTGC-3’, 5’-CCATGGCTTCCACAATGCTCATGCC-3’.101‘ 102

All primers

were purchased from GIBCO BRL. Preliminary experiments were performed to establish
the linearity range and optimal annealing temperatures for each PCR reaction. In all
cases, the cDNAs were heated at 94°C for 30 s, annealed for another 30 s, and subjected
to a 72°C extension for I min. The PCR reaction for Collagen I and HI was performed at
an annealing temperature o f 60°C for 36 cycles. RNA was also amplified using the
PDGF-A primers for 35 cycles at an annealing temperature o f 58°C. The reaction for
cyclophilin was performed under the same conditions as for the respective target genes.
The PCR products were electrophoresed on a 1% agarose gel and stained with ethidium
bromide. The band signal intensity was measured by densitometry using an EagleEye
System (Stratagene) and quantitated using SigmaGel software (Jandel Scientific).
GraphPad Instat software was utilized for statistical analysis o f experimental means,
standard error, and analyses o f variance.

Results are expressed as the ratio (mean +

SEM) o f target mRNA vs. cyclophilin housekeeping control mRNA.
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CH A PTER VI
THE ROLE OF INTEGRIN AND PDGF RECEPTOR SIGNALING IN
THE EARLY VSMC RESPONSE TO PRESSURE STIM ULUS

Introduction
To briefly summarize, wall stress is believed to be the major determinant
underlying the development o f vascular hypertrophy in hypertension. Current literature
supports the theory that increased wall stress is "sensed" (via mechanotransduction
mechanisms) by the vascular smooth muscle cells (VSMC) which then initiates an
integrated intracellular signaling pathway leading to iong-term cellular modification.
Evidence is accumulating that this process may be coordinated through cellular
attachments between the ECM and the cytoskeleton and/or via mechanically sensitive
transmembrane growth factor receptors.

Integrins sense changes in the extracellular

environment by direct attachment to components in the ECM and neighboring cells.
FAK associates with integrins, focal adhesion complexes, and growth factor receptor
tyrosine kinases. Upon phosphorylation, FAK provides a substrate for association with
and activation o f other cytosolic proteins, including Src. FAK-Y397 is the major site of
FAK autophosphorylation and serves as docking site for the Src homology (SH2/SH3)
domain o f Src.34

Therefore, FAK is a potential candidate for initiation o f the

phosphoregulatory cascade. However, Src originating from other activated receptors may
have the ability to migrate and stimulate pathways via SH2/SH3 binding domains,
including FAK37’103 and RTKs. Src-Y418 is a major site o f autophosphorylation, and Src-
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Y215 can be phosphorylated by the PDGF receptor.52 Therefore, the question to be
answered is whether FAK, Src, ERK 1/2, or PDGF-R autophosphorylation is the
initiating event, or is it a collaborative effort?

Methods
In order to delineate the intracellular signaling pathway in the initial phase of
acute hypertension, pairs o f rat mesenteric arteries were cannulated onto tapered glass
pipettes in a dual-vessel chamber.

Once secured, the vessels were pressurized in a

stepwise fashion (15 mmHg every 15 min) to a mean arterial pressure o f 90 mmHg. The
vessels were allowed to equilibrate at 90 mmHg for one hour, at which point one was
raised to 140 mmHg for I, 3, 5, or 10 minutes. The vessel remaining at 90 mmHg was
used to serve as an experimental normotensive control.

Immediately following the

experiment, both vessels were snap-frozen in liquid nitrogen and then homogenized in
RIPA buffer containing protease and phosphatase inhibitors. Western blotting was
performed on these samples to determine the presence o f activated FAK, Src, and ERK
1/2 by using phosphorylation-specific antibodies to FAK-pY397, Src-pY2ts, Src-pY418,
and p-ERK 1/2. Once this information was gathered, inhibitors were employed to further
delineate the sequence o f involvement.
O f the Src tyrosine kinase inhibitors (PP1, PP2, and herbimycin) tested in our lab,
PPl appeared to be the most potent and was used in the following experiments.104
Tyrphostin AG 1296 is a highly selective PDGF receptor kinase inhibitor that has little
effect on the EGF-R, FGF-R, VEGF-R, or Src kinase activity and was also utilized.105’
106.107

inhibitors are not yet available.
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Wesselman et al in our laboratory recently showed that Src inhibition attenuates
ERK 1/2 activation and c-fos induction in pressurized isolated vessels.53 Therefore, we
utilized PP1 (10 pM) to identify changes in FAK-Y397 phosphorylation in the absence of
Src activation. We also confirmed the efficacy o f PPl by evaluating its effect on SrcY418 phosphorylation. Finally, we used AG 1296 (10 pM) to examine the effect of PDGF
receptor inhibition on downstream ERK 1/2 activation.

Results
Ninety-three pairs o f rat first-order mesenteric arteries were utilized in this study.
During the isolated vessel experiments, the arteries responded to the incremental
increases in pressure in a passive manner. Each 15 mmHg pressure increase resulted in a
corresponding increase in lumen diameter and circumferential wall stress. Use o f the Src
tyrosine kinase inhibitor, PPl (10 pM), or the PDGFR inhibitor, AG 1296 (10 pM), did
not appear to influence these vessel characteristics. Occasionally, pressures o f 90 mmHg
or 140 mmHg triggered a moderate myogenic response. As wall stress is believed to be
the key determinant in the vascular growth response to hypertension, and myogenic tone
has been shown to attenuate the pressure-induced c-fos expression, these vessels were not
included in the study.6
The following results are presented as mean ± SEM. GraphPad Instat software
was used for determination o f mean and SEM, followed by paired t-test for statistical
significance. The null hypothesis was rejected at P<0.05, and n depicts the number of
paired experiments.
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In order to determine the involvement o f focal adhesion kinase, Src, and ERK 1/2
in the initial events o f pressure mechanotransduction, we examined the temporal
phosphorylation patterns o f these cellular components within the first 10 minutes o f acute
hypertension.

Western blotting with a phosphorylation-specific primary antibody to

FAJC-pY397 was performed on 21 pairs o f vessels subjected to pressure stimulus for I, 3,
or 5 minutes. As shown in Figure 6, one minute at 140 mmHg revealed no significant
change (P>0.05, n=6) in FAK-Y397 activation as compared to experimental control
vessels at 90 mmHg. However, 3 minutes at 140 mmHg increased FAK-pY397 1.9 + 0.24
fold over control (PO .O l, n=6), and by 5 minutes was elevated 2.54 + 0.33 fold over the
90 mmHg control (P<0.001, n=9). These results show that FAX tyrosine residue 397 is
not immediately autophosphorylated by high pressure, but becomes significantly
activated by 3 and 5 minutes o f pressure stimulus.
To further unravel cellular events during the acute phase o f hypertension, we
investigated the effect of pressure on Src-Y215 and Src-Y418 phosphorylation.

Western

blotting using a primary antibody to Src-pY215 was performed on vessel homogenates
from a total of 25 paired experiments. The results indicate that activation o f Src-Y215 is
not involved in the first I, 3, or 5 minutes o f pressure challenge (see Figure 7). However,
Src-pY418 appears to be a key player in the initial events.

Western blotting with a

phosphorylation-specific primary antibody to Src-pY418 was utilized to evaluate pressureinduced activation at 1,3, and 5 minutes. Results based on the analysis o f 15 vessel pairs
indicate a substantial 2.54 + 0.16 fold increase (P<0.001, n=5) in Src-Y418
phosphorylation at 1 minute, 2.86 + 0.22 fold increase (P 0 .0 0 1 , n=5) at 3 minutes, and
a return to baseline (P>0.05, n=5) following 5 minutes o f pressure stimulus. These
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results clearly demonstrate a significant involvement o f Src-pY418 in the initial cellular
response to acute hypertension.
With regard to ERK 1/2, Wesselman et al in our laboratory has previously
demonstrated consistent Erk 1/2 phosphorylation following 5 minutes o f pressure
stimulus.53 As an additional measure, we wanted to duplicate these results in our system.
Western blotting using a phosphorylation-state specific antibody to p-ERK 1/2 was used
to analyze vessel homogenates o f experiments conducted at 1,5, and 10 minutes o f acute
hypertension. At one minute o f pressure stimulus no significant change in ERK 1/2
activation was apparent (P>0.05, n=5), whereas by 5 minutes p-ERK 1/2 levels were
significantly elevated by 3.22 + 1 .0 fold over baseline values (P<0.01, n=7). However,
by 10 minutes, ERK 1/2 phosphorylation had returned to baseline values (P>0.05, n=5)
(see Figure 8). The ERK-MAPKs are clearly involved in pressure-mechanotransduction,
but their activation occurs later in the signaling sequence than Src and FAK.
Src-pY418 is significantly activated by I minute at 140 mmHg, and is followed by
FAK-Y397 phosphorylation at 3 and 5 minutes. To determine if FAK-Y397 activation is
Src-dependent, 9 additional paired experiments were performed on PPt treated vessels.
PP1 was selected for these experiments for its superior ability to inhibit Src activity based
on previous work in our laboratory which compared the efficacy o f Herbimycin A, PPl,
and PP2 in similar vessel experiments.53 Western blotting using the primary anti-FAKpY397 antibody revealed that PPl completely blocked FAK-Y397 activation at 1,3, and 5
minutes o f pressure stimulus (see Figure 6). These results demonstrate the requirement
o f Src tyrosine kinases in the downstream pressure-induced activation o f FAK-Y397.
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Our next step was to evaluate the influence o f PDGF receptor inhibition on
pressure-mediated signaling events. Based on our previous finding that Src-Y215 is not
activated within the first 5 minutes o f pressure stimulus, and that Src is required for
downstream ERK 1/2 activation, we felt that the PDGF receptor may not be activated
directly by pressure, but instead may be a target o f Src-pY418. In that way, signaling
pathways may be operating in parallel to collaborate in mechanotransduction.

We

considered the possibility that integrin and PDGF receptor signaling pathways may
converge in downstream activation o f ERK 1/2. Since we have demonstrated that ERK
1/2 activation peaks at 5 minutes o f pressure stimulus, we examined the effect o f PDGF
receptor inhibition on ERK 1/2 phosphorylation at 5 minutes o f pressure challenge.
However, results indicate that PDGF receptor inhibition does not attenuate downstream
ERK 1/2 activation, and that levels of p-ERK 1/2 in the presence or absence o f AG 1296
remained consistently elevated at 5 minutes of 2.76 + 0.32 vs. 3.22 ± 1.00 fold over
baseline, respectively (P>0.05, n=7) (see Figure 8). However, the possibility remains that
the PDGF receptor may be involved at a latter stage o f the pressure-mediated growth
response.

Discussion
Our long-term goal has been to characterize the pressure-induced hypertrophic
growth response in vascular smooth muscle. The ERK-MAPKinase pathway has been
linked to the cellular growth response. Activated ERK 1/2 has been shown to translocate
to the nucleus where it stimulates ternary complex factors (TCF) to bind serum response
factor (SRF).

The TCF-SRF complex then binds to the serum response element (SRE)
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within the promoter o f immediate early proto-oncogenes such as c-fos, c-jun, and c-myc.
The newly synthesized fos protein has been shown to then dimerize with jun to form the
AP-l transcription factor, which modulates the expression o f key growth regulatory
genes. 5 5-57.60.61
ERK 1/2 appears to be activated by growth factor receptor tyrosine kinases
(RTK), integrin receptor engagement, angiotensin AT-1 receptor stimulation, and
mechanical strain.

Hu et al. have demonstrated ERK1/2 activation following

autophosphorylation o f RTKs in response to cell stretch, in the absence of growth
factors.77 Li et al. have recently shown that cyclic stretch o f aortic smooth muscle cells
induces ERK 1/2, JNK, and p38, as well as MAPK phosphatase-1.62,65 Mechanical stress
may also stimulate ERKl/2 through the action of c-Src, which is associated with focal
adhesion kinase (FAK) at focal adhesion sites.66 Wesselman et al. demonstrated that
ERK 1/2 activity peaks at 5 minutes of pressure stimulus in isolated small mesenteric
arteries and subsequently gives rise to an increased expression o f the immediate early
gene, c-fos. Src inhibition using PPl, PP2, or Herbimycin A not only blocked c-fos
expression, but also inhibited ERKl/2 activation.53 Collectively, work in our laboratory
has shown that Src tyrosine kinases mediate pressure-induced ERK-MAP Kinase
activation and c-fos expression, and that this response is correlated to wall stress.3,6,53,58
The next step in our investigation was to target events upstream of ERK 1/2
activation in an effort to identify the initial cellular trigger o f the pressure-induced
signaling cascade. Cellular components at or near the plasma membrane were the targets
of this investigation. Integrins seemed like an ideal candidate due to their ability to sense
and react to changes in cell adhesion, shear stress, and mechanical strain, through direct

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

46

interaction with the extracellular matrix. Src and FAK are key components o f integrin
signaling, and are also involved in growth factor receptor tyrosine kinase pathways. In
the present study, we demonstrate that acute hypertension triggers immediate Src-Y418
autophosphorylation in intact isolated resistance arteries, and is required for downstream
activation o f FAK-Y397. The involvement o f FAK reinforces the growing body of
evidence that suggests the potential collaboration among integrins and growth factor
receptor tyrosine kinases in the pressure response.70
Hu et al. demonstrated that mechanical strain can activate the PDGF-Ra in the
absence o f ligand.77 Interestingly, EGF and PDGF receptors are colocalized within focal
adhesion sites.67, 68 Stover et al. recently showed that activation o f the PDGF receptor
triggers phosphorylation o f Src at tyrosine residue 215.52 In the present study we probed
for the presence o f Src-pY215 in pressurized vessels and our findings demonstrated an
absence o f Src-pY215 activity at any time point investigated. This suggests that prior
PDGF receptor phosphorylation is not necessary for Src activation.

Furthermore, we

have found that selective PDGF receptor inhibition with AG 1296 failed to blunt ERK
1/2 activation at 5 minutes o f pressure challenge. However, a few possibilities remain:
I) that PDGF receptor signaling converges at a point downstream o f ERK 1/2, or 2) the
PDGFR may not actually be mechanically sensitive, but is instead a target o f activated
Src, FAK, or even ERK 1/2.108 Mechanical strain has been shown to increase the
expression o f PDGF-AA and its receptor, and therefore suggests that the acute signaling
pathway may initiate a more long-term response through the increased production and
autocrine action o f PDGF.76
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Overall, the current study provides evidence that Src-pY418 may be the messenger
that initiates the cascade and propagates the signal to other key players such as FAK.
The results o f these experiments are incorporated into Figure 9 that depicts a theoretical
signaling mechanism by which hypertension stimulates cellular growth in vascular
smooth muscle cells. The remaining question is what activates Src? The mechanism by
which Src, a cytosolic component, becomes activated remains unclear, although reactive
oxygen species (ROS) have recently been implicated.46 Reactive oxygen species and
growth factors stimulate similar intracellular signal transduction events including
activation o f Src kinase family members and extracellular signal-regulated kinases
(ERKl/2). A potentially important downstream effector o f Src and ERKl/2 is p90
ribosomal S6 kinase (p90RSK), which plays an important role in cell growth by
activating several transcription factors. Abe et al found that Fyn (Src family member) was
essential for H2 O1 stimulated ERKl/2 and p90RSK activity, suggesting a redox-sensitive
mechanism o f Ras and p90RSK regulation.109 In addition, H^Ch-activated Src has been
shown to transactivate growth factor receptors such as the epidermal growth factor
receptor (EGF-R), which may amplify the signaling cascade.110 Therefore, pressurestimulated production o f ROS may be the initial trigger activating Src which in turn
phosphorylates and activates FAK, the PDGF receptor, and other members o f the
mechanotransduction cascade.

However, a mechanism by which mechanical strain

causes immediate oxidative stress has yet to be identified. Another possibility is that Src
itself is mechanically sensitive.

In an isolated tendon preparation, Banes et al have

demonstrated that cyclic mechanical loading induces rapid Src phosphorylation within 5
seconds, and reaches a plateau within 30 seconds. They hypothesized that Src is part o f a
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Figure 9.
Diagrammatic representation of the theoretical mechanism by
which hypertension stimulates vascular smooth muscle hypertrophy. Our findings
suggest that increased wall stress triggers the activation o f c-Src. which then
becomes associated with focal adhesion kinase (FAK) at focal adhesion sites.
Downstream, the ERK-MAPK pathway mediates
c-fos expression and
subsequent upregulation o f critical growth regulatory components. The PDGF
receptor does not appear to involved in the acute phase o f mechanotransduction.
but may play a role in long-term vascular remodeling. The red circles indicate
phosphorylation steps.
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mechanosensory complex linking integrins to the cytoskeleton, and attribute this response
to perturbations in the cytoskeleton that may induce a conformational change in Src
leading to enhanced kinase activity.111
In conclusion, we have shown that Src autophosphorylation is an early event in
pressure-mediated signaling in isolated resistance vessels. In addition, we have shown
that Src is required for downstream activation o f FAK and ERK 1/2, although the
relationship between them remains unclear. The PDGF receptor does not appear to be
involved within the first 5 minutes o f pressure stimulus, but may act further downstream
and/or contribute to long-term vascular remodeling.
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CHAPTER VH
THE ROLE OF PDGF AND ITS R EC EPTO R IN LONG-TERM
ARTERIAL REM O DELING

Introduction
In pressurized isolated resistance vessels we have shown that the “acute phase” o f
hypertension involves the initiation of an intracellular phosphoregulatory signaling
cascade which utilizes Src, FAK, and ERK 1/2, and culminates in altered gene
expression.

We hypothesize that this acute phase sets the stage for transition into a

chronic phase, during which time arterial remodeling is initiated and persists as long as
the pressure or wall stress remains elevated.
The vascular changes associated with chronic hypertension include medial
hypertrophy of the large conduit arteries which transitions towards inward eutrophic
remodeling as vessels enter the resistance circulation.

This response appears to be

governed by changes in wall stress, where WS = Pr/WT. The large arteries increase their
wall thickness (WT) and the small arterioles reduce their radius (r), both o f which
counteract increases in wall stress (WS). However, the mechanism by which wall stress
triggers long-term arterial remodeling has yet to be fully elucidated.
Recent evidence has suggested that growth factors and/or their receptors may be
mediators in the pathway towards smooth muscle hypertrophy within the vessel wall.
Initially, angiotensin II acting via the ATI receptor was believed to regulate vascular
growth and remodeling although evidence is accumulating that implicates Platelet
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Derived Growth Factor, specifically PDGF-AA. Wang et al previously demonstrated that
remodeling o f large and small arteries in angiotensin H-induced hypertensive rats was
paralleled by an increased expression o f platelet-derived growth factor (PDGF)-A chain
mRNA, but only in the hypertrophied large arteries.112 In non-renin-dependent l-kidney1-clip (IK1C) hypertensive rats, Parker et al demonstrated that ATI inhibition with
losartan fails to inhibit the VSMC hypertrophy.73 Dobrian et al later showed that PDGFA, but not PDGF-B, mRNA expression is upregulated in 1K1C hypertensive rats, and
that the expression directly correlated with blood pressure and wall area.75 Berk et al
reported that All-mediated hypertrophy o f vascular smooth muscle cells requires the
presence of PDGF-AA.74 In spontaneously hypertensive rats (SHR), Kitami et al have
shown that increased PDGF-AA production directly contributes to the hypertrophy of
vascular smooth muscle cells (VSMC), and also found increased mRNA expression of
the PDGF alpha receptor (PDGFRa).76 Taken together, these data suggest a direct effect
o f elevated pressure on PDGF-AA expression, which may be involved in the onset and
progression o f vascular hypertrophy.
The purpose o f our current study was to evaluate the ability o f PDGF-AA to
induce hypertrophy in large arteries of normotensive rats, and also to examine the effect
o f PDGF receptor inhibition on hypertensive remodeling and extracellular matrix
production.

Methods
Phase 1 o f the study involved local delivery of PDGF-AA to the perivascular
space around the right carotid artery.

Male Wistar rats (228-395 g) were randomly

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

52

divided into three groups: PDGF-AA 24 ng/d (n = 6), PDGF-AA 48 ng/d (n = 5), or
sterile saline-infused controls (n = 5). All rats were anesthetized using ketamine-HCl (80
mg/kg IP) and xylazine (12 mg/kg), and given a prophylactic dose o f penicillin G (25,000
U EM). Using sterile technique, the right carotid artery was carefully isolated and freed
o f surrounding tissue. The proximal end o f a specially designed catheter (microrenathane
tubing perforated at the site o f saline or PDGF-AA delivery) was secured parallel and
adjacent to the right carotid.100 Once secure, the distal end o f the catheter was tunneled
subcutaneously around the base o f the lateral right neck and between the scapulae. The
catheter was then flushed with PDGF-AA or sterile saline and attached to a miniosmopump (Alzet Model 2002, Alza Corp, Palo Alto, CA) implanted between the
scapulae. The pumps were filled with saline, PDGF-AA [2 ng/pl] or [4 ng/pl] to deliver
the desired dosage at 0.5 |ii/hr x 14 days.
In order to distinguish hypertrophy from hyperplasia, all rats were given BrdU
(5,-bromo-2’-deoxyuridine), which is readily incorporated into the DNA o f replicating
cells, in their drinking water (0.8 mg/mi) for the duration of the study.113 The animals
were housed one per cage to ensure the consumption and enable the calculation of the
dose o f dHiO/BrdU received
After 14 days, all rats were anesthetized (sodium pentobarbital 60 mg/kg IP) and
both carotid arteries (the left was used as a self-control) and the remaining kidney (BrdU
control) were harvested. The tissues were fixed in 10% phosphate-buffered formalin,
dehydrated in a stepwise fashion through graded concentrations o f ethanol, and then
embedded

in paraffin

for

immunohistochemistry

and

morphometric

analysis.

Immunohistochemistry was performed on paraffin-embedded carotid sections to
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determine the presence and distribution o f PDGF-A chain.

Tissues were first

deparaffinized and rehydrated in graded ethanols. Endogenous peroxidase was blocked
by incubation in 0.3% H2 O 2 in cold methanol, and nonspecific binding was blocked by
incubation with 5% normal goat serum (NGS) in PBS/0.1%BSA. The sections were then
incubated with

a

polyclonal

rabbit

anti-human

antibody

(dilution

1:100

in

PBS/NGS/0.1%BSA, overnight at 4°C in humidification chamber) that recognizes both
human and rat PDGF-A chain.114 After successive washings in PBS and PBS/0.l%BSA,
the slides were incubated with the biotinylated 2° goat anti-rabbit antibody (dilution
1:500 in PBS/0.1%BSA for 30 min) (Vector Laboratories, Burlingame, CA). Next, the
slides were washed prior to incubation with Vectastain Elite avidin-biotin complex kit,
and then with 0.1% diaminobenzene (DAB) Metal/Stable Peroxide Buffer. Finally, the
slides were counterstained with Gill’s hematoxylin, dehydrated and coverslipped.
Immunocytochemistry was also performed on paraffin-embedded sections to
identify cells actively undergoing DNA synthesis via the incorporation o f bromodeoxyuridine (BrdU). Carotid and kidney sections were deparaffinized, rehydrated, and
blocked for endogenous peroxidases. DNA was denatured and histones were dissociated
by treatment with 2N HC1 for 30 minutes at 37°C, then enzymatically pretreated with
trypsin, and blocked with 5% normal goat serum (NGS). Tissues were then incubated
with either mouse monoclonal anti-BrdU (1:200) or 5% NGS (negative control sections).
All tissues were rinsed and then incubated with biotinylated secondary antibody IgG
(1:400), stained with Vectastain Elite avidin-biotin complex kit, and incubated with 0.1%
diaminobenzene (DAB) in Stable Peroxide Buffer.

Kidneys from each animal were

evaluated for the incorporation o f BrdU as a positive control.
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In addition, thin sections (5 pm) o f paraffin-embedded tissues were stained with
toluidine blue for measurement o f wall area and lumen diameter using the JAVA digital
edge-tracking software. The mean of three measurements was used in the calculation of
wall area and lumen diameter.

The data was statistically interpreted using one-way

analysis o f variance. Results are presented as mean + SEM and n = number of rats.
Phase 2 o f this study involved the characterization o f vascular remodeling in onekidney-1-clip (IBCIC) hypertensive rats vs. uninephrectomized normotensive (IBCNC)
controls in the absence o f PDGF receptor activation by using CGP 53716, a selective
inhibitor o f the PDGF receptor kinase.115 Male Wistar rats (163-210 g; Harlan Sprague
Dawley, Indianapolis, IN) were randomly divided into four groups: IBCIC + CGP (n = 7),
IK1C + vehicle (n = 8), IBCNC + CGP (n = 6), and IBCNC +■ vehicle (n = 5). All rats
were anesthetized using ketamine-HCl (80 mg/kg IP) and xylazine (12 mg/kg), and given
a prophylactic dose o f penicillin G (25,000 U IM). The IK1C technique involved the
placement o f a silver clip (230 pm gap width) around the left renal artery followed by
removal o f the right kidney.116 In the control rats the left renal artery was isolated in the
same manner as in the 1BCIC technique although without clip placement, and was
followed by right uninephrectomy. Beginning post-operative day 3, all rats received a
daily IP injection o f either CGP 53716 (50 mg/kg IP; 10 mg/ml in 0.9% sterile saline, 5%
DMSO, and 1% Tween 80)117' 118 or an equivalent dose o f vehicle.
The onset and development of hypertension was tracked by measuring the systolic
tail-cuff blood pressure using a Narco Biosystems Electro-Sphygmomanometer
(Houston, TX). Measurements were taken on wanned conscious rats beginning the day
prior to surgery and then every third day postoperatively (days 3, 7, 10, and 13) until
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completion o f the study. The average o f three pressure tracings was recorded for each
measurement.
After 14 days, all rats were anesthetized (sodium pentobarbital 60 mg/kg IP) and
then sacrificed by decapitation. The thoracic and abdominal aorta, femoral artery, and
small mesenteric arteries were harvested and prepared for evaluation. One segment of
each vessel was fixed in 10% phosphate-buffered formalin, dehydrated in a stepwise
fashion through graded concentrations o f ethanol, and then embedded in paraffin for
histolologic and morphometric analysis, as previously described. Thin sections (5 pm)
paraffin-embedded tissues were rehydrated through graded ethanols and either stained
with toluidine blue for measurement o f wall area and lumen diameter using the JAVA
digital edge-tracking software, or stained for collagen using Pico-Sirius Red and
evaluated for collagen content using Scion (NIH) digital software. The mean o f three
measurements was used in the calculation o f wall area, lumen diameter, and collagen
content.
Another piece from each vessel was immediately homogenized in guanidine
isothiocyanate and p-mercaptoethanol (BME) to liberate RNA from the tissue. This was
then separated from DNA and proteins with a cold ethanol precipitation and total RNA
recovered using a GlassMax RNA Micro-isolation Spin Cartridge System (GEBCO).
Total RNA was then reverse transcribed using the Promega Reverse Transcription
System (Cat. # A3500). The cDNA was then amplified using Taq&EAD Hot Start
Polymerase (Promega, Cat.# M5661), dNTPs, MgCh and primer pairs for either Collagen
I, Collagen HI, or PDGF-A. Cyclophilin was used as the reference housekeeping gene.
The

following

rat

sequences

were

used

as

primers:

1)

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

COL

I:

5’-

56

TGCCGTGACCTCAAGATGTG-3 ’, 5 ’-CACAAGCGTGCT-GTAGGTGA-3 ’; 2) COL
IE: 5 ’-AGATC ATGT CTTC ACT CAAGTC-3 ’, 5’-TTTACATTGCCATTGGCCTGA-3’;
3) PDGF-A: 5’-AAGCATGTGCCGGAGAAGCG-3\ 5’-TCCTCTAACCTCACCTGGAC-3’; and 4) Cyciophilin: 5 ’-GTCGCGTCTGCTTCGA-GCTGTTTGC-3 \

5’-

CCATGGCTTCCACAATGCTCATGCC-3’.101’102 In all cases, the cDNAs were heated
at 94°C for 30 s, annealed for another 30 s, and subjected to a 72°C extension for I min.
The PCR reaction for Collagen I and III was performed at an annealing temperature of
60°C for 36 cycles. cDNA was also amplified using the PDGF-A primers for 35 cycles at
an annealing temperature o f 58°C. The reaction for cyciophilin was performed under the
same conditions as for the respective target genes.

The PCR products were

electrophoresed on a 1% agarose gel and stained with ethidium bromide. The band signal
intensity was measured by densitometry using an EagleEye System (Stratagene) and
quantitated using SigmaGel software (Jandel Scientific). Results are expressed as the
ratio (mean + SEM) of target mRNA vs. cyciophilin housekeeping control mRNA.

Results
For the PDGF-AA perivascular infusion study, GraphPad Instat software was
used to perform a one-way ANOVA to evaluate the effect o f PDGF-AA on vessel
structure as compared to control groups. For the CGP-53716 study, Number Cruncher
Statistical Systems (NCSS 2000) software was utilized to perform two-way analyses of
variance in order to identify the combined and individual contribution o f hypertension
and drug treatment on measured outcome across all study populations. All results are
presented as experimental means + standard error, and n = number o f rats.
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Our goal was to evaluate the ability o f the PDGF-AA isofonn to stimulate
hypertrophy in the smooth muscle cells within the carotid wall in vivo. We began by
performing morphometric analyses on toluidine blue stained carotid sections using JAVA
digital edge-tracking software. In normotensive rats that received a direct continuous
perivascular infusion o f PDGF-AA for 14 days, cross-sectional wall area was
significantly increased (P < 0.05) in the right PDGF-AA infused carotids as compared to
both the left untreated carotid from the same animals and the saline treated experimental
controls (see Figure 10). There was no significant difference between the 24 ng/d and the
48 ng/d treatment groups (P > 0.5) suggesting that 24 ng/d was sufficient to elicit the
maximal growth response. This increase was not accompanied by an enlargement o f the
vessel lumen, calculated as internal diameter, which remained consistent across the study
groups. Such findings are indicative o f outward hypertrophy.
Our experimental design permitted the direct perivascular infusion o f PDGF-AA
around the right carotid artery for 14 days. However, the ability o f PDGF to penetrate
through the adventitia and into the media was uncertain.

Therefore, in order to

characterize the presence and distribution o f PDGF-AA within the carotid wall we
performed immunohistochemistry on paraffin-embedded carotid cross-sections. The
staining was unevenly distributed but significantly more pronounced in the wall of
PDGF-AA treated vessels as compared to the left carotid (self control) and carotids o f
saline-infused animals. Staining was seen primarily in the media and subintimal layers.
There was also an enhanced staining o f the adventitial layer compared with control
arteries. The same pattern o f distribution was observed in all specimens examined, albeit
the intensity o f the staining slightly varied with each section. The staining seemed to be
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specific for PDGF-AA because the negative controls sections were consistently free of
staining.

The possibility that the PDGF-AA that was detected was endogenously

produced was also considered, although sections from same-animal left carotid controls
failed to stain in the same maimer (see Figure 11).
Thus far, we have shown that carotid arteries exposed to PDGF-AA in vivo
exhibit outward hypertrophy, and confirmed that perivascular PDGF-AA delivery
penetrates all layers o f an intact vessel in our experimental system. However, we have
yet to determine whether PDGF-AA triggers hypertrophy or hyperplasia in the vascular
wall. To answer this question, we administered 5-Bromo-2-DeoxyUridine (BrdU) in the
drinking water o f all rats for the duration o f the study. BrdU is a pyrimidine analog of
thymidine which is selectively incorporated into cell DNA during the S phase o f the cell
cycle. Therefore, BrdU will identify cells that have undergone proliferation/hyperplasia
and will not be incorporated into the DNA o f hypertrophic cells. However, BrdU cannot
distinguish hyperplasia from polyploidy.

Immunocytochemistry was performed on

paraffin-embedded carotid cross-sections using a mouse monoclonal anti-BrdU antibody
(Sigma) and revealed no significant nuclear staining for BrdU within the vessel media in
any o f the treatment groups. A few sparse endothelial or subintimal smooth muscle cells
appeared to demonstrate specific staining, although this finding was inconsistent and may
have been the result o f polyploidy or antibody trapping at the luminal border. Adventitial
fibroblasts from both saline and PDGF-AA treated carotids demonstrated consistent
staining

as

well

as

the kidney

positive control

sections

(see
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Figure 11. Immunohistochemistry using anti-PDGF-AA antibody. Images
A.B.C.D represent the saline (NS) treated experimental group. A: Right carotid
(NS delivered via implanted catheter): B: Right carotid (IHC control): C: Left
carotid (non-treated self control): D: Left carotid (IHC control). Note the
absence of positive staining. Images E.F.G.H represent the PDGF-AA (24 ng'd)
treated experimental group (R6). E: Right carotid (PDGF-AA delivered via
implanted catheter): F: Right carotid (IHC control): G: Left carotid (non-treated
self control): H: Left carotid (IHC control). Note the positive staining in slide E.
Images LLKX represent the PDGF-AA (48 ng/d) treated experimental group
(R12). I: Right carotid (PDGF-AA delivered via implanted catheter): J: Right
carotid (IHC control): K.: Left carotid (non-treated self control): L: Left carotid
(IHC control). Note the positive staining in slide I.
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Figure 12. Immunocytochemistry using anti-BrdU antibody. Images A. B. C. D
represent the saline treated group. A: Right carotid (infused): B: Right carotid ICC
control: C: Left carotid untreated self control: D: Left carotid ICC control. Images E.
F. G. H represent the PDGF-AA (24 ng/d) group. E: Right carotid (infused): F: Right
carotid ICC control: G: Left carotid untreated self control: H: Left carotid ICC control.
Images I. J. K. L represent the PDGF-AA (48 ng/d) group. I: Right carotid (infused): J:
Right carotid ICC control: K.: Left carotid untreated self control: L: Left carotid ICC
control. Images M. N are kidney sections used as experimental controls. M: positive
control: N: ICC control
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Systolic blood pressures as measured by the tail-cuff method were significantly
elevated above control levels in IK1C rats starting postoperative day 4 and continued to
rise until study completion on day 14. At day 4, measurements indicated a significant
increase (P<0.001) in the IK IC rats (1K1C-CGP 143 + 3.6, and IK1C 142.5 +
5.26 mmHg) as compared with control rats (IKNC-CGP 122.5 + 2.14 and 1KNC 122 +
3.00 mmHg). This trend continued throughout the duration o f the study and by day 14
the IK1C-CGP rats reached 184.3 + 6.3 and LKIC rats were 188.8 + 5.57 whereas
control rats remained near baseline pressures (IKNC-CGP

117.5 + 4.03 and IBCNC

115.0 + 4.18 mmHg) (see Figure 13). CGP-53716 had no apparent influence on the
development o f hypertension.
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Dobrian et al in our laboratory previously showed that PDGF-A mRNA is
significantly upregulated in IK. 1C hypertensive rats, and we have also provided evidence
that PDGF-AA stimulates outward hypertrophy in large arteries. The next step was to
determine if PDGF receptor inhibition has any influence on arterial remodeling in
hypertensive rats. In our IK IC hypertensive model, we found that CGP-53716 had little
effect on pressure-induced hypertrophy in the thoracic aorta.

Both the hypertensive

groups demonstrated a significant increase in both wall area (P < 0.0001) and lumen
diameter (P < 0.01) as compared to normotensive controls. Measurements taken from the
femoral arteries (FA) o f these same rats showed a similar trend in wall area (P < 0.0001)
and lumen diameter (P < 0.00001) in both IKIC groups over both normotensive controls.
In sections taken from the small mesenteric arteries (SMA) there was also a significant
increase in wall area (P < 0.005), although lumen diameter remained constant (P > 0.05)
across all study groups (see Figure 14). Overall, both large and small arteries from
hypertensive rats demonstrated pressure-dependent outward hypertrophy, and treatment
with CGP-53716 had no apparent effect on this response.
We further investigated the possibility that PDGF may contribute to arterial
remodeling by regulating ECM collagen production.

This was accomplished by

measuring total collagen content in CGP-treated and non-treated normotensive and
hypertensive rats. Thoracic and femoral cross-sections were stained with Pico-Sirius red
to identify collagen in the vessel wall, and NIH Scion imaging software was used to
calculate the percent collagen. The average o f four measurements per section was then
multiplied by the wall area to yield total collagen content. In thoracic sections, there was
no significant difference between IK IC and 1KNC untreated rats (P > 0.05), but there
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was a significant reduction in 1K1C CGP-treated rats as compared to 1K1C untreated (P
< 0.001). We also found a significant overall reduction in collagen content in CGPtreated versus untreated rats. However, in femoral sections, we found no significant
variation (P > 0.05) between any o f the experimental groups (see Figure 15).
Since collagen I and HI are the most abundant components in the vascular ECM
we also used RT-PCR to identify changes in their expression in response to pressure
and/or PDGF receptor inhibition. Sections o f thoracic aorta and femoral arteries from all
study groups were analyzed. To standardize the measurements, collagen I and HI mRNA
expression was compared to cyclophilin mRNA as the internal control, and the
collagenrcyclophilin ratio was used for statistical analysis. Results indicated a significant
reduction in collagen I (P < 0.05), but not HI (P > 0.05), mRNA expression in the
thoracic aortas o f CGP-treated animals as compared to their untreated counterparts (see
Figure 16). This finding parallels the reduction o f total collagen content seen in thoracic
cross-sections.

In the femoral artery, we found no significant (P > 0.05) change in

collagen I or HI expression between any o f the experimental groups (see Figure 17),
which also corresponds to the measured collagen content.

Discussion
The vascular changes associated with chronic hypertension include outward
medial hypertrophy o f the large conduit arteries which transitions towards inward
eutrophic remodeling as vessels enter the resistance circulation.

However, the

mechanism(s) which governs this vascular growth response has yet to be fuUy elucidated.
In SHRs, Negoro et al found increased PDGF-A expression in VSMCs and suggested that
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blood pressure modulates its expression to promote hypertrophy within the vessel wall.119
Wang et al found enhanced expression o f PDGF-A within the arterial wall o f All-induced
hypertensive rats.112 Previous studies in our laboratory showed that PDGF-A, but not
PDGF-B, mRNA expression is increased in 1KIC hypertensive rats, and that the
expression is directly correlated to pressure.

In addition, the study also revealed

increased PDGF-AA protein localized primarily within the medial layers o f the vessel
wall. The fact that PDGF acts in an autocrine and paracrine manner, suggests a possible
role in hypertensive remodeling.
The purpose o f the first phase o f our study was to further evaluate the ability o f
PDGF-AA to directly stimulate growth within vascular smooth muscle in a large artery o f
normotensive rats. Results from the study identified a significant increase in the wall
area o f PDGF-AA-treated carotids as compared to both saline-treated and same-animal
controls, which provided evidence that PDGF-AA does indeed induce vascular smooth
muscle growth in vivo. In addition, the lumen diameters o f all study groups remained
constant, which suggests that the infusion triggered outward growth.

We further

delineated the potential contribution of hyperplasia, polyploidy, and hypertrophy in this
response by simultaneously treating all rats with BrdU, a thymidine analog.

As

evidenced by the lack o f positive BrdU incorporation in all experimental tissues, the
growth response was consistent with hypertrophy. Overall, data from our study suggests
that PDGF-AA triggers an outward hypertrophic growth response in a manner similar to
that seen in hypertensive remodeling.
The next phase o f the study was designed to identify the effect o f PDGF receptor
inhibition on vascular hypertrophy and ECM modification in chronic hypertensive
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remodeling. Previous studies conducted by Fukuda et al found that treatment with the
antisense oligodeoxynucleotide to PDGF-A mRNA inhibits the arterial growth in
spontaneously hypertensive rats without altering their blood pressure.101 This finding
provided further support o f our hypothesis linking the PDGF receptor to vascular
remodeling. We performed similar studies in 1K1C hypertensive rats using CGP-53716,
a highly selective inhibitor o f PDGF receptor protein tyrosine kinase activity. At the end
o f the 14 day experimental period, we examined large and small arteries for changes in
wall area, lumen diameter, total collagen content and collagen I and HI mRNA
expression.
Our results indicate that PDGF receptor inhibition with CGP 53716 does not
block the hypertensive hypertrophic response in the thoracic aorta, femoral arteries, or
small mesenteric arteries. However, we found significant changes in extracellular matrix
composition. In sections taken from the thoracic aorta, total collagen content was greatly
reduced in the CGP-treated hypertensive rats as compared to the untreated IK. 1C group,
although in femoral sections we found no significant change in total collagen between
any of the experimental groups. These findings are consistent with our RT-PCR data
which identified a similar trend in collagen I mRNA expression. Holloran et al provided
further support by demonstrating that PDGF-AA is a requisite cofactor for the expression
o f collagen I mRNA in VSMCs.94 In addition, Rice et al found that inhibition o f the
PDGF receptor significantly reduced collagen synthesis in myofibroblasts.120 Therefore,
differences in ECM production between the aorta and femoral arteries may reflect a
different time course for ECM remodeling or may signify inherent variations in vessel
structure. Overall, it appears that activation o f the PDGF receptor is not an absolute
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requirement for hypertrophic remodeling in IK1C hypertension, but may play a pivotal
role in ECM modification.
Our findings are supported by a growing body o f evidence that suggests that
vascular remodeling is a coordinated effort between several growth factors and their
receptors. In VSMCs isolated from SHRs, Satoh et al found enhanced expression of
PDGF-A-chain, transforming growth factor (TGF)-betal, and basic fibroblast growth
factor (bFGF) mRNAs as compared to cells from normotensive Wistar Kyoto rats, and
suggested that these growth factors collaborate in the growth response.96 Itoh et al
demonstrated that AH induces VSMC hypertrophy via upregulation o f PDGF-AA. TGFP, and bFGF.121 Iwasaki et al reported that mechanical stress triggers ERK 1/2 activation
and can stimulate growth in VSMCs via the epidermal growth factor receptor (EGF-R),
and does not require activation o f the PDGF receptor.122

These data suggest the

involvement o f other receptors that may be operating in parallel or become upregulated in
the absence o f PDGF receptor signaling.
Recently, the potential role o f oxidative stress in hypertensive vascular
remodeling has also been emphasized. Production o f reactive oxygen species (ROS),
normally generated as byproducts of enzymatic processes in cellular metabolism, may
accelerate under pathologic conditions thus leading to oxidative stress. Bae et al have
shown that signaling through the PDGF receptor can trigger enhanced H2 O2 production
via PBK-dependent stimulation o f NADPH oxidase.123

Several laboratories have

identified redox-sensitive intracellular signaling components which are known to be
involved in cellular growth. HiOi-activated Src has been shown to transactivate growth
factor receptors such as the epidermal growth factor receptor.110 Other potentially
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important downstream effectors o f Src are ERK1/2 and p90 ribosomal S6 kinase
(p90RSK), which play an important role in cell growth by activating translational
machinery and stimulating protein synthesis.

Abe et al found that Fyn (Src family

member) was essential for H2 O2 stimulated ERK1/2 and p90RSK activity, and suggested
a redox-sensitive mechanism o f Ras and p90RSK regulation.109 Rao et al found that
ERK 1/2, JNK and p38 may also be redox-sensitive and contribute to AP-l mediated
transcription.124 Data gathered by Jin et al show that H2 O2 increases egr-1, fra-1, and cjun mRNA levels in vascular smooth muscle cells in a tyrosine kinase dependent
manner/125
Collectively, these findings may offer another piece o f the puzzle linking PDGFAA with vascular remodeling in hypertension. The present study has demonstrated a
crucial role for PDGF-AA in hypertensive ECM modification, and has not ruled out the
possibility that PDGF-AA contributes to hypertrophic remodeling. Therefore, we believe
that PDGF is one o f many messengers in a complex integrated signaling network
triggered by mechanical stress to promote vascular remodeling.
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CHAPTER VIII
CONCLUSION

Elevated blood pressure is associated with varying degrees o f arterial growth and
remodeling.

We believe that the critical factor regulating vascular remodeling in

hypertension is circumferential wall stress, which is transmitted through the ECM to all
cells within the vessel wall.

However, the mechanisms by which extracellular

mechanical stress is sensed and converted into intracellular alterations in signal
transduction and gene expression have yet to be fully elucidated. In the cell where the
goal is to maintain equilibrium, and the balance between phosphorylation and
dephosphorylation o f signaling molecules determines cellular outcome, what ultimately
shifts the cell into a growth phase and triggers ECM production? Numerous studies have
been performed to evaluate the various signaling pathways associated with the cellular
response to external stimuli.

In the acute phase o f hypertension, we have recently

demonstrated that cytosolic Src tyrosine kinases are required for ERK-MAPKinasemediated c-fos expression in pressure-stimulated rat small mesenteric arteries.33
However, the source o f their activation was largely unknown. Cellular components at or
near the cell surface were the next targets of our investigation.

Our attention was

immediately drawn to the integrin receptors which link the ECM to the cytoskeleton,
although some investigators also suggested involvement o f mechanically-sensitive
growth factor receptors.77 We also believed that growth factors and/or their receptors
were probably involved in long-term process o f vascular remodeling. This was supported
by Dobrian et al in our laboratory who found increased expression o f PDGF-A mRNA
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and protein within the vascular wall in 1KIC hypertensive rats. Therefore, the goal of
our continued endeavors has been to further characterize the mechanisms by which
VSMCs sense changes in wall stress, transmit this information to the nucleus, and
orchestrate long-term modifications at the tissue level. More specifically, the focus of the
current studies was to determine the role o f focal adhesion kinase (FAK), Src, and the
PDGF receptor in the initiation and long-term propagation o f these cellular events
towards vascular remodeling.
We chose to investigate Src and FAK because o f their known association with
integrin and growth factor receptor tyrosine kinase (RTK) signaling.

Within the Src

molecule, tyrosine 418 has been identified as the primary site o f autophosphorylation and
tyrosine 215 is known to be phosphorylated following recruitment to an activated PDGF
receptor.

FAK also associates with integrins, focal adhesion complexes, and growth

factor receptors. Upon phosphorylation, FAK provides a substrate for association with
and activation o f other cytosolic proteins, including Src. FAK-Y397 is the major site of
FAK autophosphorylation and serves as docking site for the Src homology (SH2/SH3)
domain o f Src. Therefore, FAK was considered as a potential candidate for initiation of
the phosphoregulatory cascade. However, Src originating from other activated receptors
may have the ability to migrate and stimulate other pathways via SH2/SH3 binding
domains.
For the acute studies, we pressurized pairs o f mesenteric arteries in a dual vessel
apparatus which permitted both an experimental hypertensive (140 mmHg) vessel and a
normotensive (90 mmHg) control vessel for each experiment. Based on previous data
which demonstrated peak ERK 1/2 activation at 5 minutes o f pressure stimulus, we
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examined the phosphorylated state o f Src and FAK at 1, 3, and 5 minutes.

Results

indicated that Src-Y418 is immediately activated within the first minute o f pressure,
whereas FAK-Y397 phosphorylation did not appear until 3 minutes o f hypertension. In
order to further characterize the relationship between Src and FAK, the experiments were
repeated using the Src-selective kinase inhibitor, PP1. We found that in the absence o f
Src kinase activity, FAK phosphorylation does not occur. Thus, we have identified a
time course in the signaling cascade in which Src-pY418 mediates the downstream
activation o f FAK-Y397 and ERK 1/2, although the involvement o f other messengers in
this sequence and absolute relationship between them remains unclear.

The PDGF

receptor does not appear to be involved in the acute setting, as evidenced by the lack of
Src-Y215 activation. This was further confirmed by repeating the experiments in the
presence o f AG 1296, a selective kinase inhibitor o f the PDGF receptor.

Results

indicated that ERK 1/2 activation at 5 minutes o f pressure was unaffected by PDGF-R
inhibition.
The next phase was designed to further evaluate the potential role of PDGF-AA in
long-term vascular remodeling. The first part o f this phase included the perivascular
carotid infusion o f PDGF-AA in normotensive rats. Results indicated that PDGF-AA is
capable o f inducing outward hypertrophy in a similar manner to that which is seen in
hypertension. The next step involved characterizing the effect o f CGP 53716, a selective
PDGF receptor kinase inhibitor, on chronic arterial remodeling.

We found that the

presence o f CGP 53716 had no effect on VSMC hypertrophy, although there was a
significant reduction in both total collagen content and collagen I mRNA expression
within the aortic wall. We conclude ;*p+2Xthat PDGF is a critical mediator o f ECM component
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production during the remodeling phase o f hypertension and we cannot rule out the
possible contribution to VSMC hypertrophy.
Overall, the present study has provided some key insight into hypertension as
seen from the cell’s perspective. In such a complex dynamic system we have identified
some o f the key players in both the acute and chronic phases o f hypertension. In the
initial phase the remaining question is what activates Src? Banes et al suggest that Src
itself is mechanically sensitive and is part o f a mechanosensory complex linking integrins
to the cytoskeleton,111 while others have implicated oxidative stress as the culprit.46 With
regard to the chronic state, several investigators have suggested that remodeling is
collaborative effort between several growth factors including PDGF, EGF, FGF, and
TGF-p.96,121’122 These unanswered questions will be the focus o f fixture investigations.
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